Ranjani Ramamurthy1, Maya Hughes2,3, Valerie Morris2, Hamid Bolouri4, Robert B Gerbing5, Yi-Cheng Wang5, Michael R Loken6, Susana C Raimondi5,7, Betsy A Hirsch5,8, Alan S Gamis5,9, Vivian G Oehler1,2, Todd A Alonzo10, Soheil Meshinchi11,12,13,14. 1. University of Washington School of Medicine, Seattle, Washington. 2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Seattle Children's Hospital, Seattle, Washington. 4. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Children's Oncology Group, Monrovia, California. 6. Hematologics, Inc, Seattle, Washington. 7. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. 8. Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota. 9. Children's Mercy Hospitals & Clinics, Kansas City, Missiouri. 10. Keck School of Medical Department of Preventive Medicine, University of Southern California, Los Angeles, California. 11. University of Washington School of Medicine, Seattle, Washington. smeshinc@fhcrc.org. 12. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. smeshinc@fhcrc.org. 13. Seattle Children's Hospital, Seattle, Washington. smeshinc@fhcrc.org. 14. Children's Oncology Group, Monrovia, California. smeshinc@fhcrc.org.
Abstract
BACKGROUND: Aberrant expression of microRNA-155 (miR-155) has been implicated in acute myeloid leukemia (AML) and associated with clinical outcome. PROCEDURE: We evaluated miR-155 expression in 198 children with normal karyotype AML (NK-AML) enrolled in Children's Oncology Group (COG) AML trial AAML0531 and correlated miR-155 expression levels with disease characteristics and clinical outcome. Patients were divided into quartiles (Q1-Q4) based on miR-155 expression level, and disease characteristics were then evaluated and correlated with miR-155 expression. RESULTS: MiR-155 expression varied over 4-log10-fold range relative to its expression in normal marrow with a median expression level of 0.825 (range 0.043-25.630) for the entire study cohort. Increasing miR-155 expression was highly associated with the presence of FLT3/ITD mutations (P < 0.001) and high-risk disease (P < 0.001) and inversely associated with standard-risk (P = 0.008) and low-risk disease (P = 0.041). Patients with highest miR-155 expression had a complete remission (CR) rate of 46% compared with 82% in low expressers (P < 0.001) with a correspondingly lower event-free (EFS) and overall survival (OS) (P < 0.001 and P = 0.002, respectively). In a multivariate model that included molecular risk factors, high miR-155 expression remained a significant independent predictor of OS (P = 0.022) and EFS (0.019). CONCLUSIONS: High miR-155 expression is an adverse prognostic factor in pediatric NK-AML patients. Specifically, high miR-155 expression not only correlates with FLT3/ITD mutation status and high-risk disease but it is also an independent predictor of worse EFS and OS.
BACKGROUND: Aberrant expression of microRNA-155 (miR-155) has been implicated in acute myeloid leukemia (AML) and associated with clinical outcome. PROCEDURE: We evaluated miR-155 expression in 198 children with normal karyotype AML (NK-AML) enrolled in Children's Oncology Group (COG) AML trial AAML0531 and correlated miR-155 expression levels with disease characteristics and clinical outcome. Patients were divided into quartiles (Q1-Q4) based on miR-155 expression level, and disease characteristics were then evaluated and correlated with miR-155 expression. RESULTS:MiR-155 expression varied over 4-log10-fold range relative to its expression in normal marrow with a median expression level of 0.825 (range 0.043-25.630) for the entire study cohort. Increasing miR-155 expression was highly associated with the presence of FLT3/ITD mutations (P < 0.001) and high-risk disease (P < 0.001) and inversely associated with standard-risk (P = 0.008) and low-risk disease (P = 0.041). Patients with highest miR-155 expression had a complete remission (CR) rate of 46% compared with 82% in low expressers (P < 0.001) with a correspondingly lower event-free (EFS) and overall survival (OS) (P < 0.001 and P = 0.002, respectively). In a multivariate model that included molecular risk factors, high miR-155 expression remained a significant independent predictor of OS (P = 0.022) and EFS (0.019). CONCLUSIONS: High miR-155 expression is an adverse prognostic factor in pediatric NK-AMLpatients. Specifically, high miR-155 expression not only correlates with FLT3/ITD mutation status and high-risk disease but it is also an independent predictor of worse EFS and OS.
Authors: Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield Journal: Blood Date: 2010-11-02 Impact factor: 22.113
Authors: Esmerina Tili; Jean-Jacques Michaille; Dorothee Wernicke; Hansjuerg Alder; Stefan Costinean; Stefano Volinia; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2011-03-07 Impact factor: 11.205
Authors: Sheri Tinnell Dorsam; Christina M Ferrell; Glenn P Dorsam; Mika Kakefuda Derynck; Ulka Vijapurkar; Daniel Khodabakhsh; Bonnie Pau; Hillary Bernstein; Christopher M Haqq; Corey Largman; H Jeffrey Lawrence Journal: Blood Date: 2003-11-06 Impact factor: 22.113
Authors: Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small Journal: Blood Date: 2007-04-17 Impact factor: 22.113
Authors: Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce Journal: Blood Date: 2008-01-10 Impact factor: 22.113
Authors: P M Neilsen; J E Noll; S Mattiske; C P Bracken; P A Gregory; R B Schulz; S P Lim; R Kumar; R J Suetani; G J Goodall; D F Callen Journal: Oncogene Date: 2012-07-16 Impact factor: 9.867
Authors: Hamid Bolouri; Jason E Farrar; Timothy Triche; Rhonda E Ries; Emilia L Lim; Todd A Alonzo; Yussanne Ma; Richard Moore; Andrew J Mungall; Marco A Marra; Jinghui Zhang; Xiaotu Ma; Yu Liu; Yanling Liu; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro C Hermida; Bodour Salhia; Stephen Capone; Giridharan Ramsingh; Christian Michel Zwaan; Sanne Noort; Stephen R Piccolo; E Anders Kolb; Alan S Gamis; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi Journal: Nat Med Date: 2017-12-11 Impact factor: 53.440
Authors: Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell Journal: Blood Date: 2017-04-21 Impact factor: 22.113
Authors: Emilia L Lim; Diane L Trinh; Rhonda E Ries; Jim Wang; Robert B Gerbing; Yussanne Ma; James Topham; Maya Hughes; Erin Pleasance; Andrew J Mungall; Richard Moore; Yongjun Zhao; Richard Aplenc; Lillian Sung; E Anders Kolb; Alan Gamis; Malcolm Smith; Daniela S Gerhard; Todd A Alonzo; Soheil Meshinchi; Marco A Marra Journal: J Clin Oncol Date: 2017-10-25 Impact factor: 44.544